3D-bioprinted osteochondral model based on hierarchical polymeric microarchitectures for in vitro osteoarthritis drug screening
International Journal of Bioprinting · 2025-09-10 · 11 (6) · 220
DOI: 10.36922/ijb025290288 ↗Abstract
Compared to conventional two-dimensional (2D) or scaffold-free three-dimensional (3D) drug screening models, biomimetic osteochondral constructs offer superior physiological relevance for studying osteoarthritis (OA) and accelerating therapeutic discovery. This study reports the development of a polymeric microarchitecture (PM)- based 3D osteochondral model for drug screening applications. Microfluidics-assisted fabrication enabled the generation of cartilage-like and osteogenic microtissues by encapsulating chondrocytes and endothelial/osteoblast cells within PMs. These multicellular aggregates were embedded in gelatin methacryloyl and assembled via 3D bioprinting into a stratified osteochondral construct. The model exhibited favorable cell viability, high proliferation, and organized microtissue formation, validating its biological functionality. An OA-like microenvironment was induced using lipopolysaccharide, significantly elevating pro-inflammatory cytokines. Treatment with diclofenac, dexamethasone, or curcumin markedly attenuated this response, reducing tumor necrosis factor-alpha, interleukin (IL)-1β, and IL-6 to 42.1, 193.5, and 193.5 pg/mL, respectively, while elevating the anti-inflammatory cytokine IL-10 to 90.2 pg/mL. Overall, this PM-based 3D osteochondral platform reproduces key features of native joint tissue and holds promise for OA research, drug screening, and regenerative medicine.
EUVIMED